A consistent cross-region signature linking synaptic and glial changes to neuropathological severity is identified, highlighting new mechanisms and potential biomarkers in Alzheimer's disease.
Abstract
Background/Objectives: Alzheimer’s disease (AD) shows marked transcriptomic heterogeneity across brain regions, limiting reproducibility. We aimed to identify robust cross-region gene signatures using meta-analysis. Methods: Differential expression (limma-voom) was performed on five bulk RNA-seq datasets (n = 230; 154 AD donors, 76 controls) from the hippocampus to cortical regions. Consensus DEGs were identified via Stouffer’s Z, random effects, and MetaVolcanoR models. Pathway enrichment and associations with Braak stage were evaluated. Validation was conducted in two independent cohorts, with predictive performance assessed using machine learning. Results: Thirty-seven consensus DEGs (16 up, 21 down; FDR ≤ 0.05) were identified across ≥4 datasets. The enrichment results revealed increased expression of glial and ECM-associated genes and decreased expression of synaptic and GABAergic genes. Thirty-six of 37 genes correlated with Braak stage, with all 37 remaining significantly associated after covariate adjustment. The signature predicted AD with AUCs of 0.784 and 0.861 for validation in two independent cohorts. Conclusions:: We identified a consistent cross-region signature linking synaptic and glial changes to neuropathological severity, highlighting new mechanisms and potential biomarkers.
BACKGROUND
Transcriptomic biomarker discovery for Alzheimer's disease (AD) has yielded numerous candidate signatures, yet many fail independent external validations due to overfitting or cohort-specific confounders. We aimed to identify a minimal reproducible gene signature and evaluate its generalizability under locke...
Fu-Qiang Chen· Computational biology and ch...· 0 citations
Background Early and accurate diagnosis is critical for intervening in the progression of Alzheimer’s disease (AD). However, traditional clinical diagnostic techniques, such as invasive cerebrospinal fluid punctures and expensive neuroimaging, struggle to meet the demands of large-scale early screening. Methods This st...
Xiao-Lan Zhang, Xiao-Tong Tang, Qian Bo et al.· Frontiers in Genetics· 0 citations
Integrative transcriptomics identified conserved central-peripheral signatures in PD and five hub genes are candidate biomarkers/therapeutic targets, offering a systems-level framework for disease mechanisms and independent cohort validation.
Ehsan Lotfi, Arsh Ketabforoush, Fereshteh Azeditehrani et al.· Bioinformatics and Biology I...· 0 citations
The AD-specific transcriptomic risk scores (TRSs) developed in this study shows promising clinical utility in AD diagnosis, differential diagnosis, and risk prediction, providing valuable translational medical evidence for early screening and precision prevention of Alzheimer's disease.
Peng-Fei Zhang, Zhongqian Juan, Jia-Lin Han et al.· European Archives of Psychia...· 0 citations
BACKGROUND
Gliomas are molecularly heterogeneous central nervous system tumors with marked variation in clinical outcome. Alzheimer's disease (AD)-associated transcriptional alterations may capture neural and immune programs relevant to glioma biology, but they do not by themselves establish a direct mechanistic relati...
Jun-Wu Fu, Xiang-Qian Ren, Cheng-Yong Yang et al.· Brain Research· 0 citations
It is indicated that a reproducible, strongly immune/interferon-skewed transcriptional signature, rather than a balanced up/down transcriptional shift, characterizes the mouse AD models analyzed here.